Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin carboxyl-terminal hydrolase 50 (USP50) is a member of the ubiquitin-specific protease (USP) family of deubiquitinating enzymes, though it is classified as a non-protease homolog in humans due to lack of catalytic acidic residues and little or no canonical deubiquitinating activity[1][3][5]. USP50 is a chromatin-associated protein that binds ubiquitin conjugates and is crucial for proper coordination of DNA replication, particularly by promoting correct selection and localization of helicases (notably WRN, RECQL4/5) and nucleases (FEN1, DNA2) at replication forks, supporting ongoing replication, maintaining telomere integrity, and aiding fork restart following genotoxic stress[1][2]. It also has regulatory roles in cell cycle progression (G2/M checkpoint), inflammasome assembly, and IL-1β production[3][5][7]. Loss or dysfunction of USP50 leads to replication stress, telomere instability, and has implications in cancer, premature aging, and hereditary genomic instability disorders[1][2][3]. No specific drugs are reported to directly target USP50 as of current knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin carboxyl-terminal hydrolase 50 (USP50).